Skip to content

July 2026

5-MeO-DMT

What July 2026's 5 new studies found, synthesized from the papers below. All 5-MeO-DMT research →

The synthesis

Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for 5-MeO-DMT, 5-methoxy-N, N-dimethyltryptamine, 5-MeO, bufo alvarius, incilius alvarius, then ranked by relevance.

Research published in July 2026 on 5-MeO-DMT is limited; the only directly relevant study is a review of patent applications describing structured 5-MeO-DMT treatment regimens for depression, suggesting a trend toward scalable and safer therapies. Other July 2026 studies focused on DMT (not 5-MeO-DMT) and found that DMT promotes human neural stem cell proliferation, has antidepressant and anxiolytic effects in mice comparable to S-ketamine, and can be produced in bacteria. The evidence is preliminary and does not provide clinical efficacy data for 5-MeO-DMT.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026
Supports

A review of recent patent applications reports that structured 5-MeO-DMT treatment regimens for depression are being developed, indicating a convergence toward scalable and safer neuropsychiatric therapies.

review

Study 35070
Supports

Brief 24-hour DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF.

in vitro experimental study

Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells. 2026
Supports

24-hour DMT treatment increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated G1 cell-cycle regulators and BDNF expression.

in vitro experimental study

N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine. 2026
Supports

DMT was as effective as S-ketamine in producing rapid and long-lasting antidepressant effects in helpless mice and also showed anxiolytic-like effects.

animal study

Reconstituting a two-step pathway for N,N-dimethyltryptamine (DMT) biosynthesis in bacteria 2026
Supports

Reconstructing a two-step bacterial pathway in E. coli produced up to 103 mg/L DMT in complex medium, with methionine supplementation increasing yields 2.8-fold and identifying methylation capacity as a key constraint.

experimental study

Points of agreement

  • DMT shows potential for promoting neural plasticity and proliferation in human neural stem cells.
  • DMT demonstrates antidepressant and anxiolytic effects in animal models, comparable to S-ketamine.
  • Scalable production of DMT via fermentation is feasible, supporting research and pharmaceutical applications.

Conflicts

  • No direct conflicts among the studies; however, the review focuses on 5-MeO-DMT while the other studies examine DMT, which are different compounds.

Gaps

  • No clinical trials or human studies on 5-MeO-DMT were reported in July 2026.
  • The review of 5-MeO-DMT is based on patent applications, not peer-reviewed clinical efficacy data.
  • Durability of effects and long-term safety of 5-MeO-DMT are not addressed.
  • The in vitro and animal studies use DMT, not 5-MeO-DMT, so applicability to 5-MeO-DMT is unclear.
  • Sample sizes and detailed methodology for the in vitro and animal studies are not fully described in the abstracts.
Browse these studies in the library